

DAFTAR PUSTAKA

- Abbott, J.D. 2015. Measuring the Effectiveness of Percutaneous Coronary Intervention. *Circ. Cardiovasc. Interv.*8: e003024.
- Abidin, Z. 2008. Faktor Risiko Penyakit Jantung Koroner pada Pasien Rawat Inap di Cardiovascular Care Unit (CVCU) Cardiac Centre RSUP Dr. Wahidin Sudirohusodo Makassar Periode Januari – Juli 2008. Skripsi
- Agustinus R, Yuniadi Y, Setianto B. 2020. Correlation Between QT Dispersion After Coronary Artery Bypass Graft and Major Cardiovascular Adverse Event. *Jurnal Kardiologi Indonesia.* 31;72-83
- Alwi I, Setiati S, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF. 2014. Infark Miokard Akut dengan Elevasi ST. Dalam: *Buku Ajar Ilmu Penyakit Dalam* Jilid II Edisi VI. Jakarta: Interna Publishing.
- Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Hussein A, *et al.* 2008. Risk factors for myocardial infarction in women and men: insights from the Interheart study. *Eur Heart J*;29(7):932-40
- Antman, E.M., Loscalzo, J. 2014. ST-Segment Elevation Myocardial Infarction, in: Kasper, D., Fauci, A., Hauser, S., Longo, D., Jameson, J.L., Loscalzo, J. (Eds.). *Harrison's Principles of Internal Medicine.* McGraw-Hill Education, New York
- Anwar B. Dislipidemia Sebagai Faktor Resiko Penyakit Jantung Koroner [Internet]. 2004 [cited 2014 Jan 12]. e-USU Repository. Available from : <http://library.usu.ac.id/download/fk/gizi-bahri3.pdf>.
- Anwar TB. 2004. Faktor-faktor risiko PJK. Medan: Bagian Ilmu Gizi Fakultas Kedokteran Universitas Sumatera Utara.
- Aswin AA, Kholidah D, Basuki R. Profil Lipid Dan Risiko Kejadian Penyakit Jantung Koroner (PJK) Pada Wanita Menopause Di Kota Malang. *Jurnal IKESMA.* 2012;Volume 8 Nomor 2:78.
- Arso IA, Setianto BY, Taufiq N, Hartopo AB. 2014. In-hospital Major Cardiovascular Event between STEMI Receiving Thrombolysis Therapy and Primary PCI. *Acta Medica Indonesiana -The Indonesian Journal of internal Medicine.* 46:124-30
- Arsenault BJ, Rana JS, Stroes SG, Després JP, Shah PK, Kastelein JJP. *et al.* Beyond low-density lipoprotein cholesterol. *JACC.* 2010;55(1):35-41
- Arpegård J, Magnusson PKE, Chen X, Ridefelt P, Pedersen NL, de Faire U, 12 Svensson P. Cystatin C Predicts Incident Cardiovascular Disease in Twins. *J Am Heart Assoc.* 2016;5:1-10. doi:10.1161/JAHA.115.003085
- Atsari TF. 2018. Nilai Indeks Syok Modifikasi, Skor TIMI, dan Skor Grace Sebagai Prediktor Kejadian Kardiovaskular Mayor Selama Masa Rawatan pada Pasien Infark Miokard Akut dengan Elevasi Segment ST. *Tesis.* Padang. Universitas Sumatera Utara.
- Aygul N. 2009. Prevalence of risk factors of ST segment elevation myocardial infarction in Turkish patients living in Central Anatolia. *Anadolu Kardiyol Derg* 2009; 9: 3- 9. Available from: URL: <http://www.nlm.nih.gov>

- Bare BG., Smeltzer SC. 2010. Buku Ajar Keperawatan Medikal Bedah. Jakarta : EGC. Hal : 45-47
- Bangalore S, Messerli FH, Ou F-S. 2010. The Association of Admission Heart Rate and In-hospital Cardiovascular Events in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: Result from 135.164 Patients in The CRUSADE Quality Improvement Initiative. *European Heart Journal* 31: 552-60.
- Bhatt, DI. 2018. Percutaneous Coronary Intervention in 2018. *JAMA*. 319(20): 2127-8.
- Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The Severe Cardiorenal Syndrome: 'Guyton Revisited'. *European Heart Journal*. 2005;26:11-17. doi:10.1093/eurheartj/ehi020
- Burazerl G, Goda A, Sulo G, Stefa J, Roshi E, Kark J. 2007. Conventional risk factors and acute coronary syndrome during a period of socioeconomic transition: Population-based case-control study in Tirana, Albania. *Croat Med J*, 48: 225-233.
- Cannon, C.P., Brindis, R.G., Chaitman, B.R., Cohen, D.J., Cross, J.T., Drozda, J.P., Fesmire, F.M., Fintel, D.J. 2013. ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: *a report of the American College of Cardiology Foundation/American Heart Association Task Force on*
- Canty JM, Duncker DJ, Scirica BM, et al. Atherosclerotic Cardiovascular disease. Dalam: Mann DL, Zipes DP, Libby P, Bonow RO, (eds) Braunwald's Heart Disease. *A Textbook Of Cardiovascular Medicine*. Edisi 10. Philadelphia: Elsevier Saunders. 2015. hal. 1029-1181.
- Chen, T.H., Chang, C.H., Lin, C.Y., Jenq, C.C., Chang, M.Y., Tian, Y.C., et al., 2019. Acute kidney injury biomarkers for patients in a coronary care unit: a prospective cohort study. *PLoS One*;7(2):e32328.
- Chew JSC, Saleem M, Florkowski CM and George PM,. 2008. Cystatin c a paradigm of evidence based laboratory medicine. in *clin biochem rev*, vol. 29, 47-62.
- Christensson AG, Grubb AO, Nilsson JA, Norrgren K, Sterner G, and Sundkvist G. 2004 Serum Cystatin C Advantageous Compared With Serum Creatinine In The Detection Of Mild But Not Severe Diabetic Nephropathy. in *journal of internal medicine*, vol. 256, 510-518.
- Christensson, A.G., Grubb, A.O., Nilsson, J.-Å., Norrgren, K., Sterner, G., Sundkvist, G. 2004. Serum cystatin C advantageous compared with serum creatinine in the detection of mild but not severe diabetic nephropathy. *J. Intern. Med.* 256, 510–518. <https://doi.org/10.1111/j.1365-2796.2004.01414>.
- Collinson PO, Gaze DC. 2007. Biomarkers of cardiovascular damage and dysfunction. *An Overview, Heart, Lung and Circulation*. 2007;16:S71–S82.

- Coll, E., Botey, A., Alvarez, L., Poch, E., Quintó, L., Saurina, A., Vera, M., Piera, C., Darnell, A., 2000. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. *Am. J. Kidney Dis. Off. J. Natl. Kidney Found.* 36, 29–34. <https://doi.org/10.1053/ajkd.2000.8237>.
- Correa, S., Morrow, D.A., Braunwald, E., Davies, R.Y., Goodrich, E.L. 2018. Cystatin C for Risk Stratification in Patients After an Acute Coronary Syndrome. *J. Am. Heart. Assoc.* 7: e009077.
- Creager M, Libby P. Peripheral Arterial Disease In: Mann DL, Zipes DP, Libby P, Bonow RO, editors. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Philadelphia: Elsevier Saunders; 2015. 1312 p.
- D'Ascenzo, F. 2012. TIMI, GRACE and alternative risk scores in Acute Coronary Syndromes: A meta-analysis of 40 derivation studies on 216,552 patients and of 42 validation studies on 31,625 patients. *Contemporary Clinical Trials*. doi: 10.1016/j.cct.01.001.
- Davies MJ. Coronary Disease The Pathophysiology of Acute Coronary Syndromes. *Heart.* 2000; 83; 361-366. Downloaded from <http://heart.bmj.com/>.
- Dharma S, Andriantoro H, Purnawan I. 2016. Characteristics, treatment and in-hospital outcomes of patients with STEMI in a metropolitan area of a developing country: an initial report of the extended Jakarta Acute Coronary Syndrome registry. *BMJ Open* :e012193. doi:10.1136/bmjopen-2016-012193.
- Dent TH. 2010. Predicting the risk of coronary heart disease. II. The role of novel molecular biomarkers and genetics in estimating risk, and the future of risk prediction. *Atherosclerosis* ;213:352–62.
- Domingueti CP, Fuzatto JA, Foscolo RB, Reis JS, Dusse LM, Carvalho MDG, Gomes KB, Fernandes AP. 2016. Association between Von Willebrand factor, disintegrin and metalloproteinase with thrombospondin type 1 motif member 13, d-Dimer and cystatin C levels with retinopathy in type 1 diabetes mellitus. *Clin Chim Acta.*;459:1–4.
- Dubey L, Guruprasad G, and Subramanyam G. 2013. Relationship between type 2 diabetes mellitus and coronary artery lesion characteristics: a single center study. Original Article. *Nepalese Heart Journal*. Volume 10 Number 1, November 2013.
- Eagle, K. A. 2004. A validated prediction model for all forms of acute coronary syndrome estimating the risk of 6-month postdischarge death in an international registry. *Journal of the American Medical Association*. doi: 10.1001/jama.291.22.2727.
- Ehsan MA, Mahmood M, Khan LF. 2012. Prediction of Major Adverse Cardiac Events of Patients with Acute Coronary Syndrome by Using TIMI Risk Index. *J. Dhaka National Med. Coll. Hos*;18(02):52-57.

- Fathila L. Gambaran profil lipid pada pasien infark miokard akut di RSUP M. Djamil Padang periode 1 Januari 2011-31 Desember 2012 (skripsi). Padang: Fakultas Kedokteran Universitas Andalas; 2015
- Filler G, Bokenkamp A, Hofmann W, Briccon TL, Martinez BC and Grubb A. 2005. Review Cystatin C as a Marker Of GFR –History, Indications, and Future Research. In *Clinical Biochemistry* .Vol 8, 1-8
- Framingham Heart Study. Coronary Heart Disease (10-risk year). [cited 2016 28 Februari]; Available from: <https://www.framinghamheartstudy.org/riskfunction/coronary-heart-disease/10-year-risk.php>.
- Galteau, M.M., Guyon, M., Gueguen, R., Siest, G., 2001. Determination of serum cystatin C: biological variation and reference values. *Clin. Chem. Lab. Med.* 39, 850–857. <https://doi.org/10.1515/CCLM.2001.141>
- G. L. Sardi, M. A. Gaglia Jr., G. Maluenda. 2012. “Outcome of percutaneous coronary intervention utilizing drug-eluting stents in patients with reduced left ventricular ejection fraction,” *American Journal of Cardiology*, vol. 109, no. 3, pp. 344–351
- Gleeson TG, Bulugahapitiya S. 2004. Contrast-induced nephropathy. *Am J Roentgenol*;183:1673– 89.
- Granger CB, Goldberg RJ, Dabbous O. 2003. "Predictors of hospital mortality in the global registry of acute coronary events." *Arch Intern Med* 163.
- Griffin BP, Topol EJ. *Manual of Cardiovascular Medicine*. Third edition. New York, Lippincott Williams & Wilkins; 2009.
- Grubb A. 2010. Non Invasive Estimation Of GFR, The Lund Model: Simultaneous Use Cystatin C And Creatinine Based GFR –Prediction Equations, Clinical Data And An Internal Quality Check. in *scandinavian journal of clinical & laboratory investigation*, vol.70, 65-70
- Hamm CW, Heeschen C, Falk E. 2006. Acute Coronary Syndromes: Pathophysiology, Diagnosis and Risk Stratification. Dalam: Camm AJ, Luscher TF, Serruys PW. *The ESC Textbook Of Cardiovascular Medicine*. Massachusetts: Blackwell Publishing. 2006. hal. 333-360.
- Hartati A., Sekarwana N., Dzulfikar,DLH. 2016. Perbedaan Laju Filtrasi Glomerulus Berdasarkan Kadar Kreatinin dan Cystatin C Serum pada Sindrom Nefrotik Anak. *Sari Pediatri* vol.16,no.5. hal 326.
- Hicks, K.A., Mahaffey, K.W., Mehran, R., Nissen, S.E. 2018. Standardized Data Collection for cardiovascular Trials Initiative (SCTI), 2018. Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. *Circulation* 137, 961–972. <https://doi.org/10.1161/CIRCULATIONAHA.117.033502>.
- Hochman JS, Cannon CP, Goodman SD, Wilcox RG, Schünemann HJ et al. 2004 . Thrombolysis and adjunctive therapy in acute myocardial infarction: the seventh ACCP conference on antithrombotic and thrombolytic therapy. *Chest Journal*. 126(3):549S- 575S.
- Herget-Rosenthal, S., Marggraf, G., Hüsing, J., Göring, F., Pietruck, F., Janssen, O., Philipp, T., Kribben, A.2004. Early detection of acute renal failure by serum cystatin C. *Kidney Int.* 66, 1115–1122. <https://doi.org/10.1111/j.1523-1755.2004.0086>.

- Herrera UJ, Carlos Jerjes-Sanchez. 2013. Risk factors, therapeutic approaches, and in hospital outcomes in mexicans with st-elevation acute myocardial infarction: the RENASICA II multicenter registry. *Cardiol* 2013; 36 (5): 241–248. Available from: URL: <http://wileyonlinelibrary.com>
- Hojts, R., Bevc, S., Ekart, R., Gorenjak, M., Puklavec, L., 1. 2006. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. *Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc.* 21, 1855–1862. <https://doi.org/10.1093/ndt/gfl073>. Hosseiny AD, Moloï S, Chandrasekhar, Farshid A. 2006. Mortality pattern and cause of death in a long-term follow-up of patients with STEMI treated with primary PCI. *Open Heart*. pp:3:1-7.
- Huon H. Gray, Keith D. Dawkins, John M. Morgan, Iain A. Simpson, 2002. Lecture notes cardiology. Edisi 4, Erlangga Medical Series, Jakarta, 107-150.
- Ibanez B, James S, Agewall S, Antunes MJ, Ducci CB, Bueno H. 2017. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST segment elevation. *European Heart Journal*. pp:1-66.
- Irwanto. 2013. Profil pasien penyakit jantung koroner di poli jantung RSUP Haji Adam Malik Medan pada tahun 2013 (skripsi). Medan: Fakultas Kedokteran Universitas Sumatera Utara.
- Japanese Society of Nephrology. Guidelines on the Use of Iodinated Contrast Media in Patients With Kidney Disease 2012. *Circulation Journal*. 2013;77:1883-1914.
- Khalid L and Dhakam SH. 2008. A review of cardiogenic shock in acute myocardial infarction. *Current Cardiology Reviews*. 4: 34-40.
- Kumar, V., Cotran, R.S., dan Robbins S.L. 2007. Buku Ajar Patologi. Edisi 7; ali Bahasa, Brahm U, Pendt ;editor Bahasa Indonesia, Huriawati Hartanto, Nurwany Darmaniah, Nanda Wulandari.-ed.7-Jakarta: EGC.
- Kyrou, I., & Tsigos, C. 2009. Stress hormones: physiological stress and regulation of metabolism. *Current Opinion in Pharmacology*, 9:787–793.
- Jernberg T. 2016. Swedeheart Annual Report 2015. In: Karolinska University Hospital Huddinge, 14186 Stockholm.
- Lamb E, Newman DJ and Price CP. 2006. Kidney Function Test', in *Tietz Of Textbook Clinical Chemistry and Molecular Diagnosis*, 4th, Saunders Elsevier, p147-Philadelphia, vol 797-835
- Laterza, O.F., Price, C.P., Scott, M.G., 2002. Cystatin C: an improved estimator of glomerular filtration rate? *Clin. Chem.* 48, 699–707.
- Le Bricon T, Leblanc I, Benlakehal M, Gay-Bellile C, Erlich D, Boudaoud S. 2005. Evaluation of renal function in intensive care: plasma cystatin C vs. creatinine and derived glomerular filtration rate estimates. *Clin Chem Lab Med* 43:953–957

- Lee M, Saver JL, Huang WH, Chow J, Chang KH, Ovbiagele B. 2010. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardio-vascular risk populations: a meta-analysis. *Circ Cardiovasc Qual Outcomes*. pp;3:675–83.[23] Gu FF, Lu SZ, Chen YD, Zhou Lilly, L. 2016. Pathophysiology of Heart Disease: A Collaborative Project of Medical Students And Faculty. 6th editio. Diedit oleh L. Lilly. Philadelphia: Wolters Kluwer.
- Lodh, M., Parida, A., Sanyal, J., Ganguly, A., 2013. Cystatin C in Acute Coronary syndrome. *EJIFCC* 24, 61–67.
- Lukito AA. 2015. Pedoman tatalaksana pencegahan penyakit kardiovaskular pada perempuan, edisi pertama. Jakarta : Perhimpunan Dokter Spesialis Kardiovaskular Indonesia; 2015.
- Mani, A.J., Edep, M.E., Brown, D.L. 2010. Pathophysiology of Acute Coronary Syndromes: Plaque Rupture and Atherothrombosis. *Card. Intensive Care* 73–86. <https://doi.org/10.1016/B978-1-4160-3773-6.10008-4>
- Malau, M. A. 2011. Hubungan Penyakit Jantung Koroner Dengan Tingkat Hipertensi Di RSUP H. Adam Malik Medan. Journal keperawatan. Fakultas Kedokteran Universitas Sumatra Utara.
- Marenzi G, Lauri G, Assanelli E, et al. 2004. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol*;44:1780-5.
- McMurray MD, Trivax JE and McCullough PA. 2009. Serum Cystatin C, Renal Filtration Function, and Left Ventricular Remodeling. in *Cirt Heart Fail*, vol.2; 86-9.
- Menon V. 2013. Ischemic Heart Disease. Dalam: *Griffin. BP editor Manual of Cardiovascular Medicine*. Edisi 4. Philadelphia: Lippincott Williams & Wilkins. hal. 1-124.
- Myers J, 2003. Cardiology Patient page – Exercise and cardiovascular health, *Circulation* 2003; 107:e2-5.
- Montecucco F, Carbone F, Schindler TH. 2015. Pathophysiology of ST-segment Elevation Myocardial Infarction: Novel Mechanisms and Treatments. *European Heart Journal*. 2015. doi:10.1093/eurheartj/ehv592.
- Morrow DA, Antman EM, Charlesworth A. 2000. TIMI Risk Score for STElevation myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous tPA for Treatment of Infarcting Myocardium Early II Trial Substudy. *Circulation*. 2000;102(17):2031-2037.
- Morcos SK, Thomsen HS, Webb JAW. 1999. Contrast Media Safety Committee of the European Society of Urogenital Radiology. Contrast-media-induced nephrotoxicity: a consensus report. *Eur Radiol*;9:1602–1613.
- Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. 2015. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. *Circulation*. pp;131(4):e29–322.

- Mulya DP. 2010. Hubungan Antara Skor Child Dengan Kadar Cystatin C pada Penderita Sirosis Hati. *Tesis*. Yogyakarta. Universitas Gadjah Mada.
- Muthappan P, Rogers A, Eagle K. 2012. Using the GRACE Risk Scores in Everyday practice. *AJM*. pp;125(2):144–7.
- Neumann, F.J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A.P., *et al.*, 2019. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eu. Heart. J.* 40: 87–165
- Newman DJ. 2002 'Cystatin C', in *Annals of clinical biochemistry*; 2002, vol 39, 89-104.
- Okura T, Jotoku M, Irita J, Enomoto D, Nagao T, Desilva VR, Yamane S, Pei Z, Kojima S, Hamano Y, Mashiba S, Kurata M, Miyoshi K, Higaki J. 2010. Association between cystatin C and inflammation in patients with essential hypertension. *Clin Exp Nephrol*; 14:584–8.
- Pardede 2001. Cystatin C dan hubungannya dengan Fungsi Ginjal pada Anak, dalam majalah *Cermin Dunia Kedokteran*, no132, 28-31.
- Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI). 2018. Pedoman Tatalaksana Sindrom Koroner Akut. Jakarta
- Plebani, M., Mussap, M., Bertelli, L., Moggi, G., Ruzzante, N., Fanos, V., Cataldi, L. 1997. Determinazione della cistatina C sierica in gestanti al momento del parto e nei loro neonati. *Pediatr. Med. Chir.* 19, 325–329.
- Prabhakar, S.K. dan Abbott, D. 2012. Factors influencing the outcomes of percutaneous coronary intervention in the stent era. *Interv. Cardiol.* 4(5):557–68.
- Precek J, Martin H, Martin S, Jiry J, Tomas A, Miloaslav A, *et al.* 2018. Prognostic value of cystatin C in relation to other markers of renal function in early prediction of hospital mortality and major cardiac adverse events in patients with ST elevation myocardial infarction treated by primary percutaneous coronary intervention. *Republic Chezh. Cor et Vasa* Volume 60, Issue 4, August 2018, Pages e352-e360
- Rahmawati AC, Zulaekah S, Rahmawaty S. 2009. Aktivitas fisik dan rasio kolesterol (HDL) pada penderita penyakit jantung koroner di poliklinik jantung RSUD DR Moewardi Surakarta. *Jurnal Kesehatan* ;2(1):11-8
- Reed CH. 2000. Diagnostic Application of Cystatin C, in *British Journal of Biomedical Science*, vol 57(4), 323-9
- Rhee JW, Sabatine MS, Lilly LS. 2011. Acute Coronary Syndromes. Bab 7. Dalam: *Lilly LS (ed) Pathophysiology of Heart Diseases*. Edisi 5. Philadelphia: Lippincott Williams & Wilkins. 2011. hal. 161-189.
- Rosmiatin, M. 2012. Analisis Faktor-Faktor Resiko Terhadap Kejadian Penyakit Jantung Koroner Pada Wanita Lanjut Usia Di RSUPN Dr. Cipto Mangunkusumo Jakarta. Fakultas Ilmu Keperawatan Universitas Indonesia. PhD Thesis.
- Rita C. 2007. Role Of Cystatine C In Kidney Function Assesment. dalam *kumpulan naskah lengkap KONAS & PIT VI PDS PATKLIN*, vol. 222-25

- Sadrnia S, Pourmoghaddas M, Hadizadeh M, Maghamimehr A, Esmaeeli M, Amipour A, et al. 2013. Factors affecting outcome of primary percutaneous coronary intervention for acute myocardial infarction. *Arya Atherosclerotic*. Pp:3;9:241-4
- Salgado, J.V., Souza, F.L., Salgado, B.J., 2013. How to understand the association between cystatin C levels and cardiovascular disease: Imbalance, counterbalance, or consequence? *J. Cardiol.* 62, 331–335. <https://doi.org/10.1016/j.jjcc.2013.05.015>
- Schoen, F., 2005. Blood Vessels. Dalam: Robbins and Cotrans Pathologic Basic Of Disease 7th.Ed . Pennsylvania: Elsevier Saunders, pp. 511-525.
- Shahab, Alwi., 2009, Penatalaksanaan Dislipidemia Pada Diabetes Melitus Tipe 2, Fakultas Kedokteran Unsri, Palembang.
- Spruill, T. M. 2010. Chronic psychosocial stress and hypertension. *Current Hypertension Reports*, 12(1): 10–16.
- Suhayatra P, Eka fitra, Afdhal. 2017. Gambaran Faktor Risiko dan Manajemen Reperfusi Pasien IMA-EST di Bangsal Jantung RSUP Dr. M. Djamil Padang. Skripsi. Medan : Medan: Fakultas Kedokteran Universitas Sumatera Utara
- Steg, P.G., James, S.K., Atar, D., Badano, L.P., Lundqvist, C.B., Borger, M.A., et al. 2012. Management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). *Eur. Heart J.* 33, 2569–2619. <https://doi.org/10.1093/eurheartj/ehs215>
- Taglieri N, Koenig W, Kaski JC. Cystatin C and Cardiovascular Risk. *Clinical Chemistry*. 2009;55(11):1932-1943. doi:10.1373/clinchem.2009.128397
- Tayeh, O., Rizk, A., Mowafy, A., Salah, S., Gabr, K., 2012. Cystatin-C as a predictor for major adverse cardiac events in patients with acute coronary syndrome. *Egypt. Heart J.* 64, 87–95. <https://doi.org/10.1016/j.ehj.03.002>
- Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. *AJR Am J Roentgenol.* 2003;181:1463-71.
- Thygesen, K., Alpert, J.S., Jaffe, A.S., Simoons, M.L., Chaitman, B.R., White, H.D. 2010. Third universal definition of myocardial infarction. *Eur. Heart J.* 33, 2551–2567. <https://doi.org/10.1093/eurheartj/ehs184>
- Unachukwu C, Ofori S. 2012. Diabetes mellitus and cardiovascular risk. *J Endocrinol.* ;7(1).
- Urbonaviciene G, Shi GP, Urbonavicius S, Henneberg EW, Lindholt JS. 2011. Highercystatin C level predicts long-term mortality in patients with peripheral arterial disease. *Atherosclerosis*;216:440–5.
- Valerian W, Syafri M, Rofinda ZD. 2015. Hubungan kadar gula darah saat masuk rumah sakit dengan jenis sindroma koroner akut di RS Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas.* 4(2):430-3.
- Verdiansyah, 2016. Pemeriksaan Laboratorium Fungsi Ginjal : Bandung.
- Villa P, Jimenez M, Soriano MC, Manzanares J and Casasnovas P. 2005. 'Serum Cystatin C Concentration as a Marker of Acute Renal Dysfunction in Critically ill Patients' in *critical care*, vol.9 no.5, 39-43.

- Wang L, Wang KS. 2016. Age differences in the association of severe physiological distress and behavioral factors with heart disease. 2013 (diunduh 11 Januari 2016). Tersedia dari: URL: [HYPERLINK http://dx.doi.org/10.1155/2013/979623](http://dx.doi.org/10.1155/2013/979623)
- Wang A, Holcslaw T, Bashore TM, Freed MI, Miller D, Rudnick MR, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. *Kidney Int.* 2000;57:1675–1680
- World Health Organization. Projections of mortality and causes of death, 2015 and 2030. World Health Organization. Geneva Cited October 1st 2018. Available from http://www.who.int/healthinfo/global_burden_disease/projections/en/
- Widimsky P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, et al. 2010. European Association for Percutaneous Cardiovascular Interventions. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. *Eur Heart J* 2010; 31(8):943-957.
- Windhausen, F., Hirsch, A., Fischer, J., van der Zee, P.M., Sanders, G.T., van Straalen, J.P., 2009. Cystatin C for Enhancement of Risk Stratification in Non-ST Elevation Acute Coronary Syndrome Patients with an Increased Troponin T. *Clin. Chem.* 55, 1118–1125.
- Yaswir, R et al. 2012. Pemeriksaan Laboratorium Cystatin C untuk Uji Fungsi Ginjal. Padang. FK. Unand.
- Y. Kobayashi, P. A. L. Tonino, B. De Bruyne. 2016. “The impact of left ventricular ejection fraction on fractional flow reserve: Insights from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) trial,” *International Journal of Cardiology*, vol. 204, pp. 206–210.
- Ziliang Ye, Haili Lu, Lamg Li, 2018. Reduced Left Ventricular Ejection Fraction Is a Risk Factor for In-Hospital Mortality in Patients after Percutaneous Coronary Intervention: A Hospital-Based Survey. [J Biomed Biotechnol](#): Vols. 1 to 2012; 2001 to 2018.
- Zhao, L., Wang, L., Zhang, Y., 2009. Elevated admission serum creatinine predicts poor myocardial blood flow and one-year mortality in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. *J Invasive Cardiol.* 2009 Oct;21(10):493-8.